REGNÂ – Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.REGN
$583.24Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $61,816,115,200.00
EPSttm : 39.66
Regeneron Pharmaceuticals, Inc.
$583.24
0.38%$2.24Float Short %
2.92
Margin Of Safety %
23
Put/Call OI Ratio
0.64
EPS Next Q Diff
-3.69
EPS Last/This Y
-1.37
EPS This/Next Y
-3.25
Price
583.2
Target Price
727.87
Analyst Recom
1.61
Performance Q
5.55
Relative Volume
0.64
Beta
0.3
Ticker: REGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | REGN | 558.24 | 0.68 | 0.70 | 42702 |
| 2025-09-09 | REGN | 556.73 | 0.68 | 1.01 | 43429 |
| 2025-09-10 | REGN | 555.77 | 0.69 | 0.31 | 44099 |
| 2025-09-11 | REGN | 567.79 | 0.68 | 0.47 | 44331 |
| 2025-09-12 | REGN | 559 | 0.68 | 0.67 | 44585 |
| 2025-09-15 | REGN | 572.76 | 0.67 | 0.72 | 43591 |
| 2025-09-16 | REGN | 574.84 | 0.68 | 0.60 | 44316 |
| 2025-09-17 | REGN | 585.5 | 0.68152173913043 | 1.8528925619835 | 44863 |
| 2025-09-18 | REGN | 598.71 | 0.70 | 0.48 | 45386 |
| 2025-09-22 | REGN | 595.72 | 0.72 | 0.17 | 39603 |
| 2025-09-23 | REGN | 567.47 | 0.69 | 0.10 | 40784 |
| 2025-09-24 | REGN | 576.5 | 0.53 | 5.55 | 49551 |
| 2025-09-25 | REGN | 555.53 | 0.67 | 0.98 | 54850 |
| 2025-09-26 | REGN | 564 | 0.67 | 0.95 | 55969 |
| 2025-09-29 | REGN | 560.58 | 0.66 | 0.32 | 54225 |
| 2025-09-30 | REGN | 560.24 | 0.66 | 0.29 | 55117 |
| 2025-10-01 | REGN | 599.66 | 0.66 | 0.22 | 55692 |
| 2025-10-02 | REGN | 597.32 | 0.64 | 0.24 | 58490 |
| 2025-10-03 | REGN | 600 | 0.64 | 0.52 | 59218 |
| 2025-10-06 | REGN | 584.91 | 0.63 | 0.78 | 57410 |
| 2025-10-07 | REGN | 582.85 | 0.64 | 0.13 | 58296 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | REGN | 558.44 | -22.6 | 54.1 | 39.37 |
| 2025-09-09 | REGN | 556.60 | -22.6 | 180.2 | 39.37 |
| 2025-09-10 | REGN | 555.79 | -22.6 | 191.1 | 39.37 |
| 2025-09-11 | REGN | 568.20 | -22.6 | 322.3 | 39.37 |
| 2025-09-12 | REGN | 559.97 | -22.6 | 118.0 | 39.37 |
| 2025-09-15 | REGN | 572.66 | -22.6 | 324.0 | 39.37 |
| 2025-09-16 | REGN | 575.06 | -22.6 | 222.4 | 39.37 |
| 2025-09-17 | REGN | 585.87 | -22.6 | 302.7 | 39.37 |
| 2025-09-18 | REGN | 598.57 | -22.6 | 322.0 | 39.37 |
| 2025-09-19 | REGN | 592.33 | -22.6 | 139.6 | 39.37 |
| 2025-09-22 | REGN | 595.68 | -22.4 | 233.0 | 39.41 |
| 2025-09-23 | REGN | 567.86 | -22.4 | -59.7 | 39.41 |
| 2025-09-24 | REGN | 576.71 | -22.4 | 284.7 | 39.41 |
| 2025-09-25 | REGN | 555.51 | -22.4 | -7.7 | 39.41 |
| 2025-09-26 | REGN | 563.90 | -22.4 | 282.5 | 39.41 |
| 2025-09-29 | REGN | 560.42 | -22.4 | 164.2 | 39.41 |
| 2025-09-30 | REGN | 561.74 | -22.4 | 208.3 | 39.41 |
| 2025-10-01 | REGN | 599.59 | -22.3 | 567.1 | 39.41 |
| 2025-10-02 | REGN | 600.81 | -22.3 | 206.5 | 39.41 |
| 2025-10-03 | REGN | 600.00 | -22.3 | 214.1 | 39.41 |
| 2025-10-06 | REGN | 584.91 | -22.3 | 59.6 | 39.41 |
| 2025-10-07 | REGN | 583.20 | -22.8 | 176.9 | 39.53 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | REGN | 0.00 | -4.39 | 2.30 |
| 2025-09-09 | REGN | 0.00 | -4.39 | 2.30 |
| 2025-09-10 | REGN | 0.00 | -4.39 | 2.30 |
| 2025-09-11 | REGN | 0.00 | -4.39 | 2.77 |
| 2025-09-12 | REGN | 0.00 | -4.39 | 2.77 |
| 2025-09-15 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-16 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-17 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-18 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-19 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-22 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-23 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-24 | REGN | 0.00 | -4.37 | 2.77 |
| 2025-09-25 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-09-26 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-09-29 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-09-30 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-10-01 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-10-02 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-10-03 | REGN | 0.00 | -4.37 | 2.92 |
| 2025-10-06 | REGN | 0.00 | -3.75 | 2.92 |
| 2025-10-07 | REGN | 0.00 | -3.75 | 2.92 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS​
12.81
Avg. EPS Est. Current Quarter
9.68
Avg. EPS Est. Next Quarter
9.12
Insider Transactions
Institutional Transactions
-3.75
Beta
0.3
Average Sales Estimate Current Quarter
3571
Average Sales Estimate Next Quarter
3609
Fair Value
717.22
Quality Score
99
Growth Score
80
Sentiment Score
86
Actual DrawDown %
51.9
Max Drawdown 5-Year %
-59.7
Target Price
727.87
P/E
14.7
Forward P/E
14.49
PEG
10.97
P/S
4.35
P/B
2.07
P/Free Cash Flow
16.04
EPS
39.69
Average EPS Est. Cur. Y​
39.53
EPS Next Y. (Est.)
36.28
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
31.37
Relative Volume
0.64
Return on Equity vs Sector %
-10.3
Return on Equity vs Industry %
3.4
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.16
EBIT Estimation
176.9
Regeneron Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 15182
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
stock quote shares REGNÂ – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGNÂ – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGNÂ – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGNÂ – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading